HER-2/neu Ile655Val Polymorphism and the Risk of Breast Cancer A Case-Control Study

被引:16
|
作者
Siddig, Awatif [2 ]
Mohamed, Abdelrahim Osman [3 ]
Kamal, Hammed [4 ]
Awad, Salma [5 ]
Hassan, Ahmed H. [5 ]
Zilahi, Erika [6 ]
Al-Haj, Mohammed [6 ]
Bernsen, Roos [7 ]
Adem, Abdu [1 ]
机构
[1] United Arab Emirates Univ, Dept Pharmacol, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[2] Sudan Univ Sci & Technol, Fac Med Lab Technol, Khartoum, Sudan
[3] Univ El Imam El Mahdi, Fac Med & Hlth Sci, Dept Biochem, Kosti, Sudan
[4] Univ Khartoum, Fac Med, Dept Surg, Khartoum, Sudan
[5] United Arab Emirates Univ, Dept Biochem, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[6] United Arab Emirates Univ, Dept Med Microbiol, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[7] United Arab Emirates Univ, Dept Community Med, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
来源
RECENT ADVANCES IN CLINICAL ONCOLOGY | 2008年 / 1138卷
关键词
breast cancer; HER-2/neu; polymorphism; risk;
D O I
10.1196/annals.1414.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic alterations of the proto-oncogene human epidermal growth factor receptor (HER-2/neu) have been shown to induce malignant transformation and metastasis. Genotyping studies have addressed the association of codon 655 isoleucine to valine polymorphism located in the transmembrane coding region and the risk of breast cancer, but the results are inconsistent. In this study, we investigated the association of HER-2/neu Ile655Val polymorphism and the risk of breast cancer in a Sudanese population. In addition, the joint effects of HER-2/neu variants and our previously reported ESR1C325G polymorphism were tested for their association with breast cancer risk. Candidate single nucleotide polymorphism (SNP) in HER-2/neu Ile655Val [db SNP rs1136200] was genotyped in breast cancer patients and in healthy controls that were randomly selected from the same age group as the patients. Genotyping was performed using a high-throughput allelic discrimination method using real-time PCR, and data on clinical features and demographic details were collected. Associations between genotype and breast cancer were assessed by means of logistic regression. The prevalence of Val/Val genotype was similar in patients of breast cancer and control subjects. In comparison with the Ile/Ile genotype, the Ile/Val had a borderline significantly (P = 0.06) higher risk of breast cancer (OR = 2.95, 95% CI: 0.97-8.96). Regarding the genotypic and allelic frequencies stratified by age and menopausal status, there were no significant associations. A significantly higher risk of breast cancer was observed among homozygous carriers of ESR1325 CC genotype and heterozygous carriers of HER-2/neu655 Ile/Val genotype (P = 0.05; adjusted OR = 4.9, 95% Cl: 1.0-24). The association of HER-2/neu Ile655Val polymorphism and the risk of breast cancer was borderline significant with the heterozygous carrier being at higher risk. However, the frequency of different polymorphic variants varies with ethnicity. The results of this study suggest that a significant gene-gene interaction between ESR1325C (previously reported) and HER-2/neu Ile655Val variants may jointly contribute to a higher risk of breast cancer.
引用
收藏
页码:84 / 94
页数:11
相关论文
共 50 条
  • [11] Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women
    Kamali-Sarvestani, E
    Talei, AR
    Merat, A
    CANCER LETTERS, 2004, 215 (01) : 83 - 87
  • [12] HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies (vol 124, pg 771, 2010)
    Lu, Su
    Wang, Zhanwei
    Liu, Hong
    Hao, Xishan
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (01) : 353 - 353
  • [13] Association between HER2 (Ile655Val) polymorphism with risk of breast cancer: An extensive meta-analysis
    Thomas, Sheena Mariam
    Iyshwarya, B. K.
    Veerabathiran, Ramakrishnan
    HUMAN GENE, 2024, 40
  • [14] HER2 Ile655Val Single Nucleotide Polymorphism in Patients with Ovarian Cancer
    Mojtahedi, Zahra
    Erfani, Nasroolah
    Malekzadeh, Mahyar
    Haghshenas, Mohammad Reza
    Ghaderi, Abbas
    Dehaghani, Alamtaj Samsami
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2013, 15 (01) : 1 - 3
  • [15] HER2 Ile655Val polymorphism and the trastuzumab-induced cardiotoxicity in women HER2 positive breast cancer
    Sanchez Ramos, J. G.
    Davila-Fajardo, C. L.
    Burillo, F.
    Gomez Pena, C.
    Martinez Gonzalez, L. J.
    Correa Vilchez, C.
    Carmona Saez, P.
    Moreno Escobar, E.
    Blancas, I.
    Fernandez, J. J.
    EUROPEAN HEART JOURNAL, 2014, 35 : 662 - 662
  • [16] Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer
    Han, X.
    Diao, L.
    Xu, Y.
    Xue, W.
    Ouyang, T.
    Li, J.
    Wang, T.
    Fan, Z.
    Fan, T.
    Lin, B.
    Xie, Y.
    ANNALS OF ONCOLOGY, 2014, 25 (06) : 1158 - 1164
  • [17] Her2Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies
    B. Madhu Krishna
    Sanjib Chaudhary
    Aditya K. Panda
    Dipti Ranjan Mishra
    Sandip K. Mishra
    Scientific Reports, 8
  • [18] Association of Her2Neu Ile655Val polymorphism with clinical characteristics, response to neoadjuvant chemotherapy and cardiac toxicity in locally-advanced breast cancer
    Alma, A.
    Arce-Salinas, C.
    Arrieta-Rodriguez, O.
    Figueroa, P.
    Castro, C.
    Santibanez, M.
    Lopez-Saavedra, A.
    Lara-Medina, F.
    Herrera-Montalvo, L. U. I. S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 142 - 142
  • [19] HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer
    Oguz Ozturk
    Emel Canbay
    Ozlem T. Kahraman
    M. Fatih Seyhan
    Fatih Aydogan
    Varol Celik
    Cihan Uras
    Molecular Biology Reports, 2013, 40 : 1813 - 1818
  • [20] Evaluation of Ile655Val HER2 polymorphism associated with cardiac toxicity following the administration of trastuzumab in women with breast cancer
    Diorio, Caroline
    Lemieux, Julie
    Cote, Marc-Andre
    Provencher, Louise
    Nadeau-Larochelle, Corinne
    Jacob, Simon
    Demers, Eric
    Tremblay-Lemay, Rosemarie
    Saint-Pierre, Christine
    Beauchemin, Michel
    Barabe, Frederic
    Laflamme, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)